Johnson & Johnson announced Jennifer Taubert will retire as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee, effective September 1, 2026.Original SEC Filing: JOHNSON & JOHNSON [ JNJ ] - 8-K - Aug. 04, 2026This is an AI-powered summary. It may…
OTTAVA launches as a table-integrated robotic surgery platform, targeting expansion in the U.S. and globally with a differentiated design, automation, and digital ecosystem. Early clinical results show strong workflow and efficiency benefits, with a roadmap for rapid indication and instrument expan…
Harvard professor and former Obama economic adviser Jason Furman discusses the Fed rate decision and the challenges facing Chairman Kevin Warsh, according to Bloomberg.The program also looks at the European Union rewriting merger rules to help create tech giants that can compete with America, and a…
Johnson & Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ DAC platform expands Johnson & Johnson’s onc…
Johnson & Johnson announced completion of the $1 billion acquisition of Firefly and a strategic collaboration plus equity investment in Sail, cutting 2026 adjusted EPS by $0.64.Key Highlights:Original SEC Filing: JOHNSON & JOHNSON [ JNJ ] - 8-K - Jul. 29, 2026This is an AI-powered summary. It may c…
Johnson & Johnson1 (NYSE: JNJ) today announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo CAR-T therapies for immune-mediated diseases. Johnson & Johnson will collaborate with Sail to advance its lead immune-mediated disease prog…
Johnson & Johnson reported results for the quarter ended 2026 with revenue of $25.31B and diluted EPS of $2.27, compared with $23.74B and $2.29 in the year-ago quarter; net earnings were $5.53B versus $5.54B a year earlier.Financial Highlights¹ Reported as “Sales to customers (Note 9)”. ² Reported…
Vanessa Broadhurst, an officer serving as EVP, Global Corp Affairs, reported a direct sale of common stock. The weighted average selling price was $251.266 per share. The total sale amount reported was $5,792,686. Following the reported transaction, Broadhurst directly owns 23,003 shares of common…
Shares of Sellas Life Sciences (SLS) jumped 3% overnight late Monday as retail traders bet that the final acute myeloid leukemia (AML) readout could turn this week’s Fox appearance into a launchpad for Big Pharma interest.SLS stock surged 12% on Friday to close at $13.19, capping a 3% weekly gain.S…
Johnson & Johnson reported operational sales growth: Innovative Medicines +6.8% led by oncology (DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE), TREMFYA, SPRAVATO, CAPLYTA; MedT
Q2 2026 saw 5.6% operational sales growth to $25.3B, with double-digit growth excluding STELARA. Full-year guidance was raised, driven by strong Innovative Medicine and MedTech launches, robust pipeline progress, and strategic acquisitions.Based on Johnson & Johnson [JNJ] Q2 2026 Audio Transcript —…
Johnson & Johnson reported second-quarter 2026 reported sales of $25.31 billion and net earnings of $5.534 billion, with diluted EPS of $2.27 and adjusted diluted EPS of $2.90. The company raised full-year 2026 guidance, increasing midpoint estimated reported sales to $101.1 billion and raising adj…
Johnson & Johnson JNJ) has quietly reemerged as one of the stronger-performing large-cap healthcare stocks in 2026.After hitting fresh all-time highs of $269 a share last week, investors are turning their attention to the healthcare giant's Q2 report, which is scheduled for Wednesday, July 15, befo…
